Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Bezuclastinib sunitinib combo shows promise in second-line GIST treatment

ASCO 2026

29 May - 2 Jun 2026

Published: 30 May 2026

Views: 0

Rating:

Save

Dr Andrew J. Wagner - Dana-Farber Cancer Institute, Boston, USA

Dr Andrew Wagner talks to ecancer at ASCO 2026 about results from a global randomised trial evaluating sunitinib plus bevacizumab for second-line treatment of gastrointestinal stromal tumour (GIST).

The combination therapy improved progression-free survival and response rates compared with sunitinib alone, leading Dr Wagner to speculate it could become a new standard of care, pending regulatory approval.

Related Videos

Screen-detectable cancers account for majority of early-onset cancer cases...

Prof Aldenise Ewing - The Ohio State University, Colombus, USA

Screen-detectable cancers account for majority of early-onset cancer cases under age 50 ( Prof Aldenise Ewing - The Ohio State University, Colombus, USA )

Trastuzumab and tucatinib enable organ preservation in HER2-positive rectal...

Dr Michael Foote - Memorial Sloan Kettering Cancer Cente, New York City, USA

Trastuzumab and tucatinib enable organ preservation in HER2-positive rectal cancer ( Dr Michael Foote - Memorial Sloan Kettering Cancer Cente, New York City, USA )

Encorafenib plus FOLFIRI improves response rates in BRAF-mutant metastatic...

Prof Scott Kopetz - MD Anderson Cancer Center, Housten, USA

Encorafenib plus FOLFIRI improves response rates in BRAF-mutant metastatic colorectal cancer ( Prof Scott Kopetz - MD Anderson Cancer Center, Housten, USA )

Zolbetuximab plus nivolumab and chemotherapy shows promising responses in...

Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan

Zolbetuximab plus nivolumab and chemotherapy shows promising responses in CLDN18.2-positive metastatic gastric cancer ( Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan )

FFX/bevacizumab plus atezolizumab improves PFS in first-line dMMR/MSI-H mCRC

Dr Caio Rocha Lima - Atrium Health Wake Forest Baptist, Winston-Salem, USA

FFX/bevacizumab plus atezolizumab improves PFS in first-line dMMR/MSI-H mCRC ( Dr Caio Rocha Lima - Atrium Health Wake Forest Baptist, Winston-Salem, USA )

Toripalimab plus chemotherapy improves 3-year survival in resectable gastric...

Dr Shu-Qiang Yuan - Sun Yat-sen University Cancer Center, Guangzhou, China

Toripalimab plus chemotherapy improves 3-year survival in resectable gastric/GEJ cancer ( Dr Shu-Qiang Yuan - Sun Yat-sen University Cancer Center, Guangzhou, China )

Physical activity reduces fatigue and improves quality of life in colorectal...

Dr Louisa Liu - Cedars-Sinai Medical Center, Los Angeles, USA

Physical activity reduces fatigue and improves quality of life in colorectal cancer survivors ( Dr Louisa Liu - Cedars-Sinai Medical Center, Los Angeles, USA )

Zanidatamab improves PFS and OS in first-line HER2-positive metastatic gastric...

Dr Elena Elimova - The Princess Margaret Hospital, Toronto, Canada

Zanidatamab improves PFS and OS in first-line HER2-positive metastatic gastric cancer ( Dr Elena Elimova - The Princess Margaret Hospital, Toronto, Canada )

Temab-A plus bevacizumab shows promising response rates in advanced colorectal...

Dr Michael Cecchini - Yale School of Medicine, New Haven, USA

Temab-A plus bevacizumab shows promising response rates in advanced colorectal cancer ( Dr Michael Cecchini - Yale School of Medicine, New Haven, USA )

More from ecancer